As a Managing Director at Golden Seeds, where I Co-Chair the Health Sector Committee, I see hundreds of pitch decks a year. I am often struck by the disconnect between the massive market opportunity in women’s health and the historical reluctance of venture capital to fund it.
For too long, “women’s health” was viewed by investors as a “niche” category—often conflated solely with reproductive health. This is a critical error. Women make 80% of the healthcare purchasing decisions in the United States. Yet, for decades, medical research and corporate strategy have been built on a male-centric model.
My career has been dedicated to correcting this. When I served as VP of Women’s Health at Humana Inc. , I saw firsthand how corporate strategy could drive health education initiatives that improved outcomes for millions of women. I learned that investing in women’s health isn’t just a moral imperative; it’s a business imperative.
Today, I wear two hats to accelerate this change. As a strategic advisor, I help women’s health companies refine their value propositions. As an investor, I look for early-stage, women-led healthcare companies that are solving high-impact problems.
The “Femtech” sector is booming, but we need more than just apps. We need innovation in cardiology, bone health, autoimmunity, and healthy aging—areas where women are disproportionately affected. We need founders who understand that clinical validation is just as important as user experience.
Through FemtechAZ, I’m working to build a community that connects these founders with the capital and mentorship they need. My message to my fellow investors is simple: If you want to solve healthcare’s greatest challenges, stop overlooking the decision-makers. Invest in women’s health. The returns—both financial and societal—are ready to be realized.
